These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 5002719)
41. [Investigations concerning the effect of synthetic "thyrotropin releasing factor" (TRF) in patients with thyroid gland function disorders and in healthy controls]. zur Mühlen A von ; Köbberling J; Hesch RD; Emrich D Acta Endocrinol Suppl (Copenh); 1971; 152():76. PubMed ID: 4101597 [No Abstract] [Full Text] [Related]
42. Thyrotropin releasing hormone (TRH) studies in patients with thyroid cancer. Samaan NA; Beceiro JR; Hill CS; Haynie TP; Glenn HJ J Clin Endocrinol Metab; 1972 Sep; 35(3):438-43. PubMed ID: 4626272 [No Abstract] [Full Text] [Related]
43. Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism. Irie M; Tsushima T J Clin Endocrinol Metab; 1972 Jul; 35(1):97-100. PubMed ID: 4624350 [No Abstract] [Full Text] [Related]
44. [On the pituitary TSH response to different dosage of thyrotropin-releasing factor (TRF) (author's transl)]. Sakoda M; Mori H; Tateiwa M; Kusaka T; Otuki M Nihon Naika Gakkai Zasshi; 1973 Nov; 62(11):1520-8. PubMed ID: 4208605 [No Abstract] [Full Text] [Related]
45. [Effect of intravenous injection of synthetic TRH in hypophyseal pathology]. Jaquet P; Codaccioni JL; Oliver C; Vague P; Carlon N; Vague J Ann Endocrinol (Paris); 1972; 33(4):331-9. PubMed ID: 4351891 [No Abstract] [Full Text] [Related]
46. Case of hyperthyroidism due to a chromophobe adenoma. Baylis PH Clin Endocrinol (Oxf); 1976 Mar; 5(2):145-50. PubMed ID: 1269160 [TBL] [Abstract][Full Text] [Related]
47. Response to synthetic thyrotropin-releasing hormone in man. Hershman JM; Pittman JA J Clin Endocrinol Metab; 1970 Oct; 31(4):457-60. PubMed ID: 4195197 [No Abstract] [Full Text] [Related]
48. Chromophobe pituitary adenoma with acromegaly and TSH-induced hyperthyroidism associated with parathyroid adenoma. Acromegaly and parathyroid adenoma. Lamberg BA; Ripatti J; Gordin A; Juustila H; Sivula A; af Björkesten G Acta Endocrinol (Copenh); 1969 Jan; 60(1):157-72. PubMed ID: 4308288 [No Abstract] [Full Text] [Related]
49. Clinical experience with human growth hormone immunoassay by a two-antibody method. Ewer RW; Deiss WP Arch Intern Med; 1969 Oct; 124(4):461-7. PubMed ID: 4309856 [No Abstract] [Full Text] [Related]
50. Acromegaly and thyrotoxicosis induced by a GH- and TSH-producing pituitary tumour which also contained prolactin. Meinders AE; Willekens FL; Barends CA; Seevinck J; Nieuwenhuijzen Kruseman AC Neth J Med; 1981; 24(4):136-44. PubMed ID: 7279084 [No Abstract] [Full Text] [Related]
51. Thyroid activation in rats after intrapituitary administration of synthetic thyrotrophin-releasing factor (TRF). Averill RL Endocrinology; 1974 Mar; 94(3):794-8. PubMed ID: 4205139 [No Abstract] [Full Text] [Related]
52. Hyperthyroidism due to thyrotropin-producing pituitary chromophobe adenoma. Hamilton CR; Adams LC; Maloof F N Engl J Med; 1970 Nov; 283(20):1077-80. PubMed ID: 5470849 [No Abstract] [Full Text] [Related]
53. Effects of synthetic pyroglutamyl-histidyl-proline-amide on serum levels of thyrotrophin, cortisol, growth hormone, insulin and PBI in normal subjects and patients with pituitary and thyroid disorders. Karlberg B; Almqvist S; Werner S Acta Endocrinol (Copenh); 1971 Jun; 67(2):288-302. PubMed ID: 4996103 [No Abstract] [Full Text] [Related]
54. Effect of pretreatment with pyridostigmine on the thyrotropin response to thyrotropin-releasing hormone in patients with Cushing's disease. Giustina A; Bossoni S; Buffoli MG; Ferrari C; Pozzi A; Scalvini T; Schettino M Horm Metab Res; 1992 May; 24(5):248-50. PubMed ID: 1398468 [No Abstract] [Full Text] [Related]
55. Effect of thyrotropin-releasing factor on serum thyroid-stimulating hormone. An approach to distinguishing hypothalamic from pituitary forms of idiopathic hypopituitary dwarfism. Costom BH; Grumbach MM; Kaplan SL J Clin Invest; 1971 Oct; 50(10):2219-25. PubMed ID: 4330007 [TBL] [Abstract][Full Text] [Related]
56. Evaluation of plasma thyrotrophin response to thyrotrophin releasing hormone in Graves' disease and in hyperactive thyroid adenoma before and after treatment. Faglia G; Ferrari C; Beck-Peccoz P; Ambrosi B; Spada A; Travaglini P; Paracchi A Folia Endocrinol; 1973 Aug; 26(4):245-56. PubMed ID: 4203132 [No Abstract] [Full Text] [Related]
57. Hyperthyroidism and high serum levels of TSH associated with pituitary tumour. Chiarini V; Graziano E; Cremonini N; Frank G; Zampa GA Neurochirurgia (Stuttg); 1987 Mar; 30(2):61-3. PubMed ID: 3106846 [TBL] [Abstract][Full Text] [Related]
58. Evidence for the release of a novel pituitary polypeptide (7B2) from the growth hormone-producing pituitary adenoma of patients with acromegaly. Natori S; Iguchi H; Nawata H; Kato K; Ibayashi H; Nakagaki H; Chrétien M J Clin Endocrinol Metab; 1988 Feb; 66(2):430-7. PubMed ID: 3123513 [TBL] [Abstract][Full Text] [Related]
59. [Effects of thyrotrophin releasing hormone]. Waldhäusl W Wien Klin Wochenschr; 1972 Jun; 84(25):412-6. PubMed ID: 4625604 [No Abstract] [Full Text] [Related]
60. [Clinical observation on the effect of synthetic thyrotropin releasing factor (TRF): examination of TRF test]. Otsuki M; Sakota M; Hiroshige N; Kanao K; Yagi A Horumon To Rinsho; 1971 Jun; 19(6):473-9. PubMed ID: 4999994 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]